13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis

Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis

Acute pediatric neurological emergencies represent high-acuity, time-sensitive transport crises where rapid diagnosis and targeted neuroprotective interventions dictate long-term cognitive and functional outcomes. Prolonged convulsive seizures and fulminant central nervous system infections (bacterial meningitis and viral encephalitis) trigger profound systemic metabolic stress, acute intracranial hypertension, and excitotoxic neuronal injury. Critical care transport clinicians must master the molecular pathophysiology of status epilepticus, execute a rapid stepwise pharmacological algorithm, anticipate secondary airway and cardiovascular compromise, and implement immediate antimicrobial and isolation protocols.

---

Neurobiology & Operational Definition of Status Epilepticus

Historically, status epilepticus (SE) was defined as continuous seizure activity lasting 30 minutes or longer, reflecting the duration required to induce permanent histological neuronal damage in animal models. However, modern neurocritical care operates under a dual-timeline operational definition:

• $T_1$ (Operational Definition — 5 Minutes): Convulsive seizure activity persisting for $\ge 5\text{ minutes}$, or two or more discrete seizures without complete recovery of consciousness between episodes. Spontaneous seizure cessation after 5 minutes is statistically improbable (<5%), and medical rescue therapy must begin immediately.
• $T_2$ (Neuronal Injury Threshold — 20 to 30 Minutes): The point at which continuous electrographic seizure activity produces irreversible cellular injury, hippocampal sclerosis, microvascular collapse, and systemic metabolic breakdown.

Continuous Seizure Activity (T = 0 to 5 min)
       │
       ▼
[T1: 5 Minutes] ──► Spontaneous Cessation Improbable; Initiate 1st-Line Benzodiazepines
       │
       ▼
Clathrin-Dependent Endocytosis of Synaptic GABA-A Receptors (Downregulation)
       │
Mobilization & Insertion of Postsynaptic NMDA & AMPA Receptors (Upregulation)
       │
       ▼
[15 to 30 Minutes] ──► Profound Pharmacoresistance to Benzodiazepines
       │
       ▼
[T2: >30 Minutes] ──► Excitotoxic Calcium Influx, Mitochondrial Collapse & Neuronal Death

The Receptor Shift: GABA Downregulation & NMDA Upregulation

The progressive failure of antiepileptic pharmacotherapy during ongoing status epilepticus is governed by rapid, time-dependent alterations in synaptic receptor trafficking:

1. GABA-A Receptor Internalization: Under physiological conditions, seizure activity is terminated by inhibitory gamma-aminobutyric acid (GABA) binding to postsynaptic GABA-A receptors, opening chloride channels and hyperpolarizing the neuronal membrane. Within 10 to 15 minutes of continuous seizure activity, synaptic GABA-A receptors undergo clathrin-dependent endocytosis and are internalized into intracellular endosomes. As functional surface GABA-A receptors become depleted, benzodiazepines (which act as positive allosteric modulators on GABA-A receptors) lose up to 10- to 20-fold of their anticonvulsant efficacy.
2. NMDA and AMPA Receptor Recruitment: Concurrently, excitatory ionotropic glutamate receptors (N-methyl-D-aspartate [NMDA] and AMPA receptors) are mobilized from subsynaptic stores and inserted into the postsynaptic density. Unopposed presynaptic glutamate release stimulates massive extracellular calcium and sodium influx through upregulated NMDA channels. Intracellular calcium overload activates calpains, caspases, and endonucleases, uncoupling mitochondrial oxidative phosphorylation and driving irreversible apoptotic and necrotic cell death.

---

Step-Wise Medical Management Algorithm for Pediatric SE

Transport teams must adhere to a standardized, time-directed resuscitation sequence, avoiding unnecessary delays between escalating therapeutic tiers.

Phase 1: 0 to 5 Minutes (Emergent Stabilization & Metabolic Screening)

• Support airway, breathing, and circulation (ABCs). Place the child in the recovery position (or keep the head elevated 15–30 degrees in the midline if intubated) and apply high-flow oxygen via a non-rebreather mask.
• Obtain continuous pulse oximetry, 3-lead/12-lead ECG, blood pressure, and waveform capnography ($EtCO_2$).
• Point-of-Care Glucose Rule: Perform an immediate bedside blood glucose check. Hypoglycemia (<60 mg/dL in infants and children; <40–45 mg/dL in neonates) must be treated immediately with Dextrose 10% in Water (D10W) at 2 to 5 mL/kg IV/IO bolus (the "Rule of 50": $mL/kg \times \%\text{ Dextrose} = 50$). Never administer concentrated D50W to infants or young children due to severe hyperosmolality and vascular sclerosis risk.
• Attempt peripheral intravenous (PIV) cannulation. If reliable IV access is not achieved within 2 attempts or 90 seconds, transition immediately to intraosseous (IO) access or utilize mucosal routes.

Phase 2: 5 to 10 Minutes (First-Line Rescue Benzodiazepines)

Administer a rapid-acting benzodiazepine immediately once seizure duration reaches 5 minutes:

• Lorazepam (Ativan): 0.1 mg/kg IV/IO (maximum single dose 4 mg), infused slowly over 1 to 2 minutes. Lorazepam is the preferred agent when IV access is established due to its high GABA-A receptor affinity, lower lipid solubility, and prolonged central anticonvulsant duration (4 to 8 hours).
• Midazolam (Versed): 0.2 mg/kg IM or Intranasal (IN) via mucosal atomizer device (MAD), or 0.1 mg/kg IV/IO (maximum single dose 10 mg). Midazolam is uniquely water-soluble at acidic vial pH, enabling rapid absorption across nasal mucosa and muscle beds. Intranasal or intramuscular midazolam achieves seizure termination faster than attempting to establish difficult IV access.
• Diazepam (Valium): 0.2 mg/kg IV/IO (maximum single dose 10 mg) or 0.5 mg/kg rectally (Diastat gel; maximum 20 mg). Diazepam is highly lipophilic; while it enters the brain within seconds, it rapidly redistributes into peripheral adipose stores, causing cerebral levels to decline within 20 to 30 minutes, predisposing to early seizure recurrence.
• Redosing Rule: If clinical convulsive seizure activity persists after 5 to 10 minutes, administer one repeat dose of the initial benzodiazepine. Transport clinicians must NEVER administer more than two total doses of benzodiazepines; exceeding two doses dramatically increases the incidence of severe respiratory depression, hypotension, and airway loss without improving seizure termination rates.

Phase 3: 10 to 20 Minutes (Second-Line Non-Sedating Antiepileptic Drugs)

If seizures persist despite two doses of benzodiazepines (established status epilepticus), immediately initiate a non-sedating second-line IV/IO antiepileptic drug (AED). Choice of agent should be guided by institutional protocol, patient allergies, and preexisting AED regimens:

• Levetiracetam (Keppra): 60 mg/kg IV/IO (maximum dose 4,500 mg), infused over 10 minutes. Levetiracetam binds selectively to synaptic vesicle protein SV2A, inhibiting presynaptic calcium-dependent exocytosis of excitatory neurotransmitters. It has zero hepatic metabolism, lacks active drug interactions, and causes minimal cardiovascular or respiratory depression.
• Fosphenytoin (Cerebyx): 20 mg PE (Phenytoin Equivalents)/kg IV/IO (maximum dose 1,500 mg PE), infused at a rate up to $150\text{ mg PE/min}$ (over 10 minutes). Fosphenytoin is a water-soluble prodrug that is converted by blood and tissue phosphatases to active phenytoin, which prolongs the inactivated state of voltage-gated sodium channels. Continuous ECG and blood pressure monitoring are mandatory during infusion due to risks of cardiac dysrhythmias (bradycardia, heart block, QT prolongation) and hypotension. Note: Unlike parent phenytoin, fosphenytoin contains no propylene glycol solvent and does not cause purple glove syndrome.
• Valproate Sodium (Depacon): 40 mg/kg IV/IO (maximum dose 3,000 mg), infused over 5 to 10 minutes. Valproate potentiates GABA synthesis and blocks voltage-sensitive sodium and T-type calcium channels. Contraindicated in children under 2 years with suspected inborn errors of metabolism or mitochondrial hepatopathies (e.g., POLG mutations).

Phase 4: >20 to 30 Minutes (Refractory Status Epilepticus & Continuous Infusions)

Seizures failing to terminate after full doses of a first-line benzodiazepine and a second-line AED represent Refractory Status Epilepticus (RSE). At this juncture, the patient requires definitive endotracheal intubation, continuous anesthetic infusions, and invasive arterial pressure monitoring:

• Definitive Airway Control: Perform rapid sequence intubation (RSI) using hemodynamically stable induction agents (Ketamine 1–2 mg/kg or Midazolam 0.2 mg/kg). Note: Administering a neuromuscular blocking agent (e.g., Rocuronium 1 mg/kg) paralyzes the peripheral musculature, stopping visible tonic-clonic convulsions, but DOES NOT terminate ongoing cerebral electrographic status epilepticus. Continuous cerebral monitoring (amplitude-integrated EEG [aEEG] or continuous EEG) is vital; transport teams must closely monitor surrogate autonomic signs of ongoing seizure activity, including unexplained pupillary dilation, tachycardia, and hypertension.
• Continuous Anesthetic Infusions:
  • Midazolam Infusion: Loading bolus of 0.2 mg/kg IV, followed by a continuous infusion of 0.1 to 2.0 mg/kg/hr titrated to electrographic burst suppression.
  • Ketamine Infusion: Loading bolus of 1 to 2 mg/kg IV, followed by 1.0 to 5.0 mg/kg/hr. As a non-competitive NMDA receptor antagonist, ketamine is mechanistically ideal for refractory status epilepticus because NMDA receptors are markedly upregulated while GABA receptors are internalized. Furthermore, ketamine supports systemic vascular resistance and blood pressure.
  • Pentobarbital / Thiopental: High-dose barbiturate therapy reserved for refractory status; induces profound myocardial depression and vasodilation, requiring aggressive crystalloid and inotropic support.
  • The Propofol Warning in Pediatrics: Avoid prolonged continuous Propofol infusions in pediatric transport. High-dose (>4–5 mg/kg/hr) or prolonged (>48 hours) propofol administration triggers Propofol Infusion Syndrome (PRIS), characterized by refractory metabolic lactic acidosis, severe rhabdomyolysis, hyperkalemia, acute hepatomegaly, hyperlipidemia, and lethal cardiogenic shock.

---

Comparison of Second-Line Antiepileptic Drugs (AEDs)

---

Pediatric Altered Mental Status & Acute CNS Infections

Altered mental status (AMS) reflects acute diffuse cerebral cortical or reticular activating system dysfunction. Transport teams should utilize the mnemonic "AEIOU TIPS" (Acidosis/Alcohol, Epilepsy/Encephalopathy, Infection, Overdose, Uremia, Trauma/Tumor, Insulin/Hypoglycemia, Poisoning, Shock/Stroke) during systematic diagnostic evaluation.

Acute Bacterial Meningitis vs Viral Encephalitis

Acute central nervous system infections represent life-threatening causes of AMS and new-onset seizures:

• Bacterial Meningitis: Intense suppurative infection localized within the subarachnoid space and leptomeninges. Pathogens cross the blood-brain barrier, triggering massive cytokine release (TNF-$\alpha$, IL-1), neutrophilic infiltration, purulent exudate accumulation in basal cisterns, microvascular thrombosis, cerebral ischemia, and acute cerebral edema.
  • Microbiology: Neonates and infants <3 months: Group B Streptococcus (GBS), Escherichia coli (K1 capsular strain), and Listeria monocytogenes. Children ≥3 months: Streptococcus pneumoniae (highest mortality and morbidity) and Neisseria meningitidis.
• Viral Encephalitis: Direct viral invasion and parenchymal inflammation of the brain parenchyma itself, leading to focal neurological deficits, neuropsychiatric symptoms, and intractable focal motor seizures.
  • Microbiology: Herpes Simplex Virus (HSV-1 and HSV-2), Enteroviruses, and Arboviruses. HSV classically invades the inferior and medial temporal lobes, producing hemorrhagic necrotizing encephalitis.

Clinical Presentation: Classical Signs vs Infant Nuances

• Older Children: High fever, severe headache, photophobia, altered mentation, and nuchal rigidity. Classic meningeal irritation signs include:
  • Kernig's Sign: Inability or severe pain upon passive extension of the knee when the patient is supine with the hip flexed at 90 degrees.
  • Brudzinski's Sign: Passive flexion of the neck induces involuntary, spontaneous flexion of the hips and knees.
• Infants & Young Children: Meningeal signs are notoriously absent in infants <12 to 18 months due to open cranial sutures and immature motor reflexes. Infants present with non-specific, insidious signs:
  • Full, tense, or bulging anterior fontanelle (evaluated while quiet and upright)
  • High-pitched, continuous, inconsolable "cat-like" cry
  • Paradoxical Irritability: The infant cries more vehemently when held and rocked by parents (because movement stretches inflamed spinal nerve roots) and quietens when left completely undisturbed on the mattress
  • Hypothermia (temperature <36.0°C) or fever, poor feeding, intractable vomiting, and lethargy
• Petechial & Purpuric Rash: Rapidly spreading petechiae progressing to coalescent ecchymoses and purpura fulminans strongly indicates Neisseria meningitidis bacteremia (meningococcemia). This presentation warrants immediate preparation for fulminant septic shock, massive capillary leak, and bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome).

---

Transport Stabilization, Antimicrobial Timing & The LP Rule

Interfacility transport of pediatric patients with suspected meningitis or encephalitis demands flawless adherence to infection control, empiric pharmacotherapy, and risk stratification:

1. Infection Control & Droplet Precautions: Immediately place the patient on strict Droplet Precautions (in addition to standard precautions). All transport crew members must wear surgical masks (or N95 respirators) and eye protection before patient contact. Maintain droplet precautions for a minimum of 24 hours following initiation of effective parenteral antimicrobial therapy. If crew members sustain unmasked exposure to respiratory secretions from confirmed meningococcal disease, post-exposure chemoprophylaxis (Rifampin 10 mg/kg PO q12h for 2 days, or a single dose of Ceftriaxone 250 mg IM or Ciprofloxacin 500 mg PO) should be initiated within 24 hours.
2. Empiric Antimicrobial Regimens:
   • Neonates and Young Infants: Regimens depend on age. Neonates receive meningitic-dose ampicillin (for Listeria and GBS) plus an extended-spectrum cephalosporin (ceftazidime or cefepime in the U.S., because cefotaxime has not been marketed there since 2018), with or without gentamicin; vancomycin is not routinely needed in the first weeks. For infants about 29–60 days old with suspected meningitis, the AAP febrile infant guideline uses ceftriaxone plus vancomycin. Caution: Ceftriaxone is avoided in hyperbilirubinemic neonates and must not be given to neonates 28 days old or younger who are receiving IV calcium-containing solutions (Section 6.5).
   • Children ≥3 Months: Ceftriaxone (100 mg/kg/day IV divided q12–24h; maximum 4 g/day) PLUS Vancomycin (60 mg/kg/day IV divided q6h; maximum 2–4 g/day, targeting serum trough concentrations of 15 to 20 mcg/mL to overcome cephalosporin-resistant S. pneumoniae).
   • Suspected HSV Encephalitis: Add IV Acyclovir (20 mg/kg IV q8h for infants <3 months; 10 mg/kg IV q8h or 500 mg/$m^2$ q8h for children ≥3 months) for any child presenting with AMS, CSF pleocytosis, focal seizures, or temporal lobe abnormalities.
3. Dexamethasone Neuroprotection Timing:
   • Dexamethasone (0.15 mg/kg IV every 6 hours for 2 to 4 days) attenuates the explosive inflammatory cascade triggered by antibiotic-induced bacterial lysis in the subarachnoid space.
   • Timing and Indications: When used, dexamethasone is given shortly before or with the first antibiotic dose; benefit is unlikely once antibiotics have been running for more than about an hour. The AAP Red Book recommends it for Haemophilus influenzae type b meningitis in infants and children 6 weeks and older (it reduces hearing loss) and says it may be considered for pneumococcal meningitis in that age group after weighing risks. It is not recommended for neonates, and it must never delay antibiotics.
4. The Lumbar Puncture (LP) Transport Safety Rule:
   • Diagnostic lumbar puncture must NEVER delay antibiotic administration or transport.
   • Absolute Contraindications to Lumbar Puncture Prior to Transport:
     1. Clinical signs of increased intracranial pressure (papilledema, Cushing's triad, pupillary asymmetry, or decerebrate/decorticate posturing). Performing an LP in the presence of uncal or tonsillar brain herniation creates a critical cranial-to-lumbar pressure gradient, precipitating fatal brainstem herniation.
     2. Severe cardiopulmonary instability, decompensated septic shock, or impending respiratory arrest.
     3. Severe coagulopathy or profound thrombocytopenia (platelets <50,000/mcL).
     4. Focal neurological deficits.
     5. Cutaneous cellulitis or anatomical infection overlying the lumbar puncture site.
   • If any contraindication exists or if performing the procedure would delay transport, draw blood cultures immediately, administer empiric antibiotics and dexamethasone, and defer the lumbar puncture until the child is fully stabilized in the tertiary pediatric intensive care unit.

---

Realistic Transport Scenario: Pediatric Status Epilepticus in Flight

A critical care transport team is dispatched via fixed-wing aircraft to retrieve a 4-year-old boy (weight 18 kg) with prolonged status epilepticus at a remote community clinic. Prior to arrival, the child experienced 25 minutes of continuous generalized tonic-clonic convulsions. The clinic physician administered two doses of rectal diazepam (10 mg each) with zero effect. On crew arrival, the patient is actively convulsing with rhythmic bilateral limb jerking, trismus, and shallow respirations. Heart rate is 174 bpm, blood pressure is 108/68 mmHg, SpO2 is 88% on room air, and point-of-care glucose is 102 mg/dL.

The transport nurse immediately applies high-flow oxygen via non-rebreather mask and establishes a proximal tibial intraosseous (IO) line within 60 seconds after peripheral IV attempts fail. Recognizing that the child has already received two doses of benzodiazepine and that continuous seizure activity for >30 minutes has triggered GABA-A receptor internalization, the team immediately bypasses further benzodiazepines to avoid respiratory arrest. The clinician loads Levetiracetam at 60 mg/kg IV/IO (1,080 mg) infused over 10 minutes via pressure bag. Waveform capnography reveals an $EtCO_2$ of 58 mmHg, indicating worsening hypoventilation.

At minute 8 of the levetiracetam infusion, tonic-clonic motor activity persists unabated. The team prepares for refractory status epilepticus and airway stabilization. The flight physician performs rapid sequence intubation using Ketamine (2 mg/kg IV) and Rocuronium (1 mg/kg IV), securing a 4.5 mm cuffed endotracheal tube on the first attempt with video laryngoscopy. A continuous Ketamine infusion is initiated at 2 mg/kg/hr to maintain NMDA-receptor blockade and hemodynamic stability. To ensure comprehensive coverage, Fosphenytoin (20 mg PE/kg = 360 mg PE) is infused under continuous ECG monitoring. By cruise altitude, the child's vital signs stabilize at heart rate 118 bpm, blood pressure 98/62 mmHg, and $EtCO_2$ 38 mmHg. The patient is transported safely to the regional pediatric neuro-ICU without seizure recurrence.

---

Clinical Pearls for Pediatric Neurological Crises